Price Alert

Akoya Biosciences Inc. (AKYA)

NASDAQ: AKYA · Real-Time Price · USD

1.29

-0.07 (-5.15%)

At close: Jul 07, 2025, 3:59 PM

Akoya Biosciences Statistics

Share Statistics

Akoya Biosciences has 49.95M shares outstanding. The number of shares has increased by 0.92% in one year.

Shares Outstanding	49.95M
Shares Change (YoY)	0.92%
Shares Change (QoQ)	0.28%
Owned by Institutions (%)	25.32%
Shares Floating	12.59M
Failed to Deliver (FTD) Shares	7
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 2.39M, so 4.79% of the outstanding shares have been sold short.

Short Interest	2.39M
Short % of Shares Out	4.79%
Short % of Float	7.89%
Short Ratio (days to cover)	3.72

Valuation Ratios

The PE ratio is -2.04 and the forward PE ratio is -1.9. Akoya Biosciences's PEG ratio is 0.09.

PE Ratio	-2.04
Forward PE	-1.9
PS Ratio	1.39
Forward PS	0.7
PB Ratio	14.9
P/FCF Ratio	-2.43
PEG Ratio	0.09

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Akoya Biosciences.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.61, with a Debt / Equity ratio of 11.08.

Current Ratio	2.61
Quick Ratio	1.78
Debt / Equity	11.08
Debt / EBITDA	-2.27
Debt / FCF	-1.81
Interest Coverage	-4.48

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$398.4K
Profits Per Employee	$-270.07K
Employee Count	205
Asset Turnover	0.65
Inventory Turnover	1.39

Taxes

Income Tax	146K
Effective Tax Rate	-0.26%

Stock Price Statistics

The stock price has increased by -43.91% in the last 52 weeks. The beta is 1.35, so Akoya Biosciences's price volatility has been higher than the market average.

Beta	1.35
52-Week Price Change	-43.91%
50-Day Moving Average	1.22
200-Day Moving Average	1.99
Relative Strength Index (RSI)	51.9
Average Volume (20 Days)	582,118

Income Statement

In the last 12 months, Akoya Biosciences had revenue of 81.67M and earned -55.37M in profits. Earnings per share was -1.12.

Revenue	81.67M
Gross Profit	47.88M
Operating Income	-46.73M
Net Income	-55.37M
EBITDA	-37.14M
EBIT	-44.79M
Earnings Per Share (EPS)	-1.12

Full Income Statement

Balance Sheet

The company has 11.78M in cash and 84.15M in debt, giving a net cash position of -72.37M.

Cash & Cash Equivalents	11.78M
Total Debt	84.15M
Net Cash	-72.37M
Retained Earnings	-285.44M
Total Assets	112.65M
Working Capital	-41.87M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -44.1M and capital expenditures -2.46M, giving a free cash flow of -46.56M.

Operating Cash Flow	-44.1M
Capital Expenditures	-2.46M
Free Cash Flow	-46.56M
FCF Per Share	-0.94

Full Cash Flow Statement

Margins

Gross margin is 58.62%, with operating and profit margins of -57.22% and -67.79%.

Gross Margin	58.62%
Operating Margin	-57.22%
Pretax Margin	-67.61%
Profit Margin	-67.79%
EBITDA Margin	-45.47%
EBIT Margin	-57.22%
FCF Margin	-57.01%

Dividends & Yields

AKYA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for AKYA is $1.65, which is 27.9% higher than the current price. The consensus rating is "Hold".

Price Target	$1.65
Price Target Difference	27.9%
Analyst Consensus	Hold
Analyst Count	4

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-4.25
Piotroski F-Score	4